MRK.VI Merck & Company Inc
- Market cap
- EUR 330B
- P/E
- 122.8x
- P/B
- 8.22x
- ROE
- -26.6%
- Dividend yield
- 2.28%
- Fundamental score
- 1.8/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is MRK.VI undervalued?
Graham numberThe Graham number of Merck & Company Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Merck & Company Inc fundamental analysis
8 of 21 checks passedROE 0/2
Low return on equity (-26.6%), below 10%.
ROA 0/1
Return on assets (-8.6%) is below the industry median (3.8%).
Profit Consistency 2/2
Profitable for 6 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (8.9%) is not above the 5-year average (21.4% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (8.9%) is below the industry median (14.7%).
Revenue Growth 1/2
Revenue grew 3.1% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 0/2
High debt to equity (121.8%), above 100%.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 2/2
Loss-making but free cash flow is positive.
PE vs Market 0/1
PE (123.8x) is above the market median (18.5x).
PE vs Industry 0/1
PE (123.8x) is above the industry median (16.6x).
PBV 0/1
Price to book (8.3x) is above the industry median (1.5x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 1,025.8, limit 22.5).
PEG 0/1
PEG on 5-year earnings growth is 5.77, above 1.
Dividend Yield 0/2
Dividend yield (0.4%) is in the bottom 25% of dividend payers in the market.
Dividend Stability 1/2
Dividends paid without a cut of more than 10% for 6 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 44.8%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Merck & Company Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Merck & Company Inc
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccine…
Full company profileMerck & Company Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Merck & Company Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 41.5B | 48.7B | 59.3B | 60.1B | 64.2B | 65.0B | 65.8B |
| Gross Profit | 27.9B | 35.1B | 41.9B | 44.0B | 49.0B | 48.6B | 48.6B |
| Operating Income | 5.55B | 13.2B | 18.3B | 2.95B | 20.2B | 22.1B | -7.27B |
| EBITDA | - | - | 21.3B | 6.91B | 25.7B | 28.3B | -236M |
| Net Income | 7.07B | 13.0B | 14.5B | 365M | 17.1B | 18.3B | -11.2B |
| EPS | 2.79 | 5.16 | 5.72 | 0.14 | 6.77 | 7.38 | -4.52 |
| Balance Sheet | |||||||
| Total Assets | 91.6B | 106B | 109B | 107B | 117B | 137B | 130B |
| Total Liabilities | 66.2B | 67.4B | 63.1B | 69.0B | 70.7B | 84.2B | 87.8B |
| Shareholders' Equity | 25.3B | 38.2B | 46.0B | 37.6B | 46.3B | 52.6B | 41.9B |
| Cash & Short-term Investments | 8.05B | 8.10B | 12.7B | 6.84B | 13.2B | 14.6B | 6.85B |
| Cash Flow | |||||||
| Operating Cash Flow | 10.3B | 14.1B | 19.1B | 13.0B | 21.5B | 16.5B | 18.6B |
| Capital Expenditure | 4.43B | 4.45B | 4.39B | 3.86B | 3.37B | 4.11B | 3.77B |
| Free Cash Flow | 5.82B | 9.66B | 14.7B | 9.14B | 18.1B | 12.4B | 14.8B |
| Ratios | |||||||
| ROE | 27.9% | 34.2% | 31.6% | 1.0% | 37.0% | 34.7% | -26.6% |
| ROA | 7.7% | 12.3% | 13.3% | 0.3% | 14.6% | 13.3% | -8.6% |
| Net Profit Margin | 17.0% | 26.8% | 24.5% | 0.6% | 26.7% | 28.1% | -16.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Merck & Company Inc dividends
- Dividend yield
- 2.28%
- Forward dividend
- 3.02 EUR
- Payout ratio
- 44.8%
- Ex-dividend date
- Sep 15, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 8.18B | 3.30 | 44.8% |
| 2024 | USD 7.84B | 3.10 | 45.8% |
| 2023 | USD 7.45B | 2.94 | 2,039.7% |
| 2022 | USD 7.01B | 2.76 | 48.3% |
| 2021 | USD 6.61B | 2.62 | 50.7% |
| 2020 | USD 6.22B | 2.46 | 87.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Merck & Company Inc
- Insiders 0.06%
- Institutions 82.88%
- Public & others 17.07%
- Shares outstanding 2.47B
- Free float 2.47B
Merck & Company Inc company profile
- Company name
- Merck & Company Inc
- Ticker
- MRK.VI
- Exchange
- Vienna Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 73,000
- Fiscal year end
- December
- Address
- 126 East Lincoln Avenue, Rahway, NJ, United States, 07065
- Phone
- 908 740 4000
- Website
- merck.com
About Merck & Company Inc
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Merck & Company Inc management
10- Mr. Robert M. Davis J.D.Chairman, President & CEO · born 1967
- Ms. Caroline A. LitchfieldExecutive VP & CFO · born 1969
- Ms. Jennifer L. Zachary J.D.Executive VP & General Counsel · born 1978
- Dr. Dean Y. Li M.D., Ph.D.Executive VP & President of Merck Research Laboratories · born 1963
- Mr. Dalton E. Smart IIISenior VP of Finance, Principal Accounting Officer & Global Controller · born 1967
- Mr. Gaurav K. GuptaExecutive Vice President and Chief Information & Digital Officer
- Mr. Peter DannenbaumVice President of Investor Relations
- Mr. Chirfi GuindoExecutive Vice President of Strategic Access, Policy & Communications · born 1966
- Ms. Betty D. LarsonExecutive VP & Chief Human Resources Officer · born 1976
- Mr. Richard R. DeLuca Jr.Executive VP & President of Merck Animal Health · born 1963